Jane Street’s Cardiol Therapeutics CRDL Stock Holding History

Jane Street’s Portfolio CRDL Stock Details CRDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$172K	Buy	126,957 +87,129	+219%	+$89.4K	﹤0.01%	10275
2025 Q4	$38K	Sell	39,828 -76,519	-66%	-$80.1K	﹤0.01%	10579
2025 Q3	$126K	Buy	+116,347	New	+$141K	﹤0.01%	10009
2024 Q4	–	Sell	-14,759	Closed	-$29.4K	–	9541
2024 Q3	$29.4K	Buy	+14,759	New	+$30.6K	﹤0.01%	9252
2023 Q2	–	Sell	-20,875	Closed	-$10.2K	–	8782
2023 Q1	$10.2K	Sell	20,875 -42,198	-67%	-$25K	﹤0.01%	8734
2022 Q4	$32.1K	Buy	+63,073	New	+$38.4K	﹤0.01%	8486
2022 Q2	–	Sell	-36,576	Closed	-$57K	–	9775
2022 Q1	$57K	Sell	36,576 -16,220	-31%	-$26.8K	﹤0.01%	9649
2021 Q4	$97K	Sell	52,796 -26,635	-34%	-$73.6K	﹤0.01%	9264
2021 Q3	$327K	Buy	+79,431	New	+$288K	﹤0.01%	8018

Other funds holding CRDL

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jane Street's CRDL Position: Q1 2026 in Review

Jane Street increased its Cardiol Therapeutics (CRDL) stake by 219% in Q1 2026, buying an estimated $89.4K and bringing the position to 126,957 shares worth $172K. The position accounts for ﹤0.01% of the portfolio, ranked #10275.

Jane Street first reported a position in CRDL in Q3 2021 and has held it in 9 quarters since. The position peaked at $327K in Q3 2021. 47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

Jane Street held 126,957 shares of Cardiol Therapeutics worth $172K as of Q1 2026.
Jane Street bought 87,129 Cardiol Therapeutics shares in Q1 2026, an estimated $89.4K.
Cardiol Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #10275 holding.
Jane Street first reported a position in Cardiol Therapeutics in Q3 2021 and has held it in 9 quarters since.
Jane Street's Cardiol Therapeutics position peaked at $327K in Q3 2021.
47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.